Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Risk Factors for New Neurological Diagnoses in Hospitalized COVID-19 Patients: A Case-Control Study in New York City
28 Pages Posted: 6 Jan 2022
More...
There are 2 versions of this paper
Risk Factors for New Neurological Diagnoses in Hospitalized COVID-19 Patients: A Case-Control Study in New York City
Abstract
Background: There have been numerous reports of neurological manifestations identified in hospitalized patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Here, we identify the spectrum of associated neurological symptoms and conditions, define the time course in the development of neurological conditions, address readmission rates and mortality risk post-hospitalization in a multiethnic urban cohort.
Methods: We identify the occurrence of neurological diagnoses among patients with laboratory-confirmed SARS-CoV-2 infection in a multi-ethnic cohort in New York City. We compare demographic and clinical features of COVID-19 patients with neurological diagnoses during hospitalization to those without neurological diagnoses in a retrospective case-control study and examine hospital-related data and outcomes of death and readmission up to 6 months after acute hospitalization in a secondary case-only cohort analysis. A retrospective cohort study was performed of 532 hospitalized patients with neurological manifestations within 6 weeks of positive SARS-CoV-2 laboratory results between March 1, 2020 and August 31, 2020.
Findings: The most common neurological diagnoses included encephalopathy (478, 77.3%), stroke (99, 16.0%), and seizures (38, 7.1%). Those with new neurological diagnoses were more likely than those without neurological diagnoses to be male (312, 58.6%), have baseline neurological comorbidities (193, 36.3%) and be treated in an intensive care unit (ICU) (330, 62.0%) [p for all comparisons < 0.0001]. Of the 394 (74.1%) cases that survived the acute hospitalization, more than half (220/394, 55.8%) were readmitted within 6 months, with a mortality rate of 23.2% during readmission.
Conclusion: Among SARS-CoV-2 infected patients, a significant burden of neurological diagnoses exists, particularly in critically ill populations. Further research is needed to define the impact of neurological diagnoses during acute hospitalization on longitudinal post-coronavirus disease 2019 (COVID-19) related symptoms including neurocognitive impairment.
Funding Information: Supported by the Centers for Disease Control and Prevention (contract 75D30120C07986 to Westat), F30 MH114390 to OJL.
Declaration of Interests: MSVE: Dr. Elkind receives royalties from UpToDate for a chapter on COVID-19 and neurological disease. Dr. Sobieszczyk was funded by a COVID supplement to the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI06947. No other interests to declare.
Ethics Approval Statement: This study received approval from CUIMC institutional review board (IRB) with a waiver of written informed consent for retrospective analysis.
Keywords: COVID-19, SARS-CoV-2, neurological diagnoses, Encephalopathy
Suggested Citation: Suggested Citation